Pulmonary hypertension - chronic thromboembolic pulmonary hypertension

The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with riociguat under the National Health Act 1953, section 100 for adult patients with CTEPH.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing riociguat.

Section 100 arrangements

riociguat

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with riociguat, patients must be treated in a centre with expertise in the management of CTEPH.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised riociguat to treat CTEPH can be made either in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised riociguat to treat CTEPH can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 4 June 2024.
QC 36186